Exhibit B

modified RF, Recovery filter. Look how much better the fracture resistance is for the G2 filter than it was for the Recovery filter. 03:35:03

Similarly, the testing showed the same thing when it comes to migration. The migration percentage is much less in the testing, the ability to avoid migration is much greater for G2 than it ever was for the Recovery filter but there's more. The guidance and what Bard did pursuant to the guidance, and even going beyond what the FDA guidance required, included many, many different types of studies. Bard worked hand in hand with the FDA. You'll see the submissions Bard made to the agency. Pages and pages of test summaries and data and the FDA didn't just say, "Okay, fine. Go sell it." The FDA came back with questions, many questions, requiring additional data. 03:35:17 03:35:41

And only after Bard answered all of their questions did the FDA eventually clear the device and it cleared the G2 three times effectively essentially. First in August of 2005, as I indicated, for permanent use. Several months later it approved a jugular delivery system for the G2 filter, and then for retrievable use in January of 2008. 03:36:08 03:36:32

Bard's collaboration with the FDA did not end there. Bard conducted what was called the EVEREST study. The study protocol had to be reviewed and approved by the FDA. Bard provided updates to the FDA on the progress of the study. Bard provided the FDA, and you will see it, with data about every 03:36:56